

Summit Corporation plc
("Summit" or "the Company")

EXERCISE OF WARRANTS

Oxford, UK, 23 August 2013, Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and *C. difficile* infection, announces that it has received notice and payment from N+1 Singer Capital Markets ('N+1') to exercise warrants over 1,000,000 Ordinary shares of 1.0 pence each at an exercise price of 5.0 pence per Ordinary share.

Summit has applied for admission of the new Ordinary shares to trading on AIM ('Admission'), a market of the London Stock Exchange. It is expected that Admission will become effective on or around 27 August 2013 and the new Ordinary shares will rank *pari passu* with existing Ordinary shares. Following Admission, the Company will have 447,357,841 Ordinary shares in issue.

- END -

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter ([@summitplc](https://twitter.com/summitplc)).

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 939

Nomura Code Securities

(Nominated Adviser and Joint broker)

Chris Collins / Jonathan Senior / Giles Balleny

Tel: +44 (0)20 77761200

Hybridan LLP

(Joint broker)

Claire Louise Noyce / William Lynne

Tel: +44 (0)207 947 4350 / 4361

Peckwater PR

(Financial public relations, UK)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)

Michelle Avery

Tel: +1 781-235-3060